Table 1. Summary characteristics of patients and control subjects in this study.
| Patients | N | Age | Sex (male/female) | HLA-DQB1*06:02 positive | Prior Pandemrix immunization | Disease duration | CSF orexin levels <110 pg/ml (N/N tested) | CSF orexin levels >200 pg/ml (N/N tested) |
|---|---|---|---|---|---|---|---|---|
| yr | mo | |||||||
| Healthy donors | 25 | 47 (13–64) | 16/9 | 25 | ||||
| Narcolepsy type 1 | 39 | 42 (13–64) | 23/16 | 39 | 11 | 59 (8–552) | 32/32 | |
| Other hypersomnias | 11 | 25 (6–54) | 3/8 | 10/10 |
For age and disease duration, numbers indicate the median with the range in parentheses.